95-13995. Manufacturer of Controlled Substances; Notice of Application
[Federal Register Volume 60, Number 110 (Thursday, June 8, 1995)]
[Notices]
[Page 30318]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-13995]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.43(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on April 5, 1995, Radian
Corporation, P.O. Box 201088, Mopac Blvd., Austin, Texas 78720, made
application to the Drug Enforcement Administration (DEA) for
registration as a bulk manufacturer of the basic classes of controlled
substances listed below:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cathinone (1235).......................................... I
Methcathinone (1237)...................................... I
N-Ethylamphetamine (1475)................................. I
N,N-Dimethylamphetamine (1480)............................ I
Aminorex (1585)........................................... I
4-Methylaminorex (cis isomer) (1590)...................... I
Methaqualone (2565)....................................... I
Lysergic acid diethylamide (7315)......................... I
Tetrahydrocannabinols (7370).............................. I
Mescaline (7381).......................................... I
3,4-Methylenedioxyamphetamine (7400)...................... I
3,4-Methylenedioxy-N-ethylamphetamine (7404).............. I
3,4-Methylenedioxymethamphetamine (7405).................. I
4-Methoxyamphetamine (7411)............................... I
Psilocybin (7437)......................................... I
Psilocyn (7438)........................................... I
Dihydromorphine (9145).................................... I
Normorphine (9313)........................................ I
Acetylemthadol (9601)..................................... I
Alphacetylmethadol except Levo-Alphacetylmethadol (9603).. I
Normethadone (9635)....................................... I
3-Methylfentanyl (9813)................................... I
Amphetamine (1100)........................................ II
Methamphetamine (1105).................................... II
Methylphenidate (1724).................................... II
Amobarbital (2125)........................................ II
Pentobarbital (2270)...................................... II
Secobarbital (2315)....................................... II
Phencyclidine (7471)...................................... II
1-Piperidinocyclohexanecarbonitrile (8603)................ II
Dihydrocodeine (9120)..................................... II
Oxycodone (9143).......................................... II
Hydromorphone (9150)...................................... II
Diphenoxylate (9170)...................................... II
Benzoylecgonine (9180).................................... II
Ethylmorphine (9190)...................................... II
Hydrocodone (9193)........................................ II
Isomethadone (9226)....................................... II
Meperidine (9230)......................................... II
Methadone (9250).......................................... II
Methadone-intermediate (9254)............................. II
Morphine (9300)........................................... II
Levo-alphacetylmethadol (9648)............................ II
Oxymorphone (9652)........................................ II
Alfentanil (9737)......................................... II
Sufentanil (9740)......................................... II
Fentanyl (9801)........................................... II
------------------------------------------------------------------------
The firm plans to manufacture deuterated and non-deuterated
analytical reference standards.
Any other such applicant and any person who is presently registered
with DEA to manufacture such substances may file comments or objections
to the issuance of the above application and may also file a written
request for a hearing thereon in accordance with 21 CFR 1301.54 and in
the form prescribed by 21 CFR 1316.47.
Any such comments, objections, or requests for a hearing may be
addressed to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, United States Department of
Justice, Washington, D.C. Federal Register Representative (CCR), and
must be filed no later than July 10, 1995.
Dated: May 31, 1995.
Gene R. Haislip,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 95-13995 Filed 6-7-95; 8:45 am]
BILLING CODE 4410-09-M
Document Information
- Published:
- 06/08/1995
- Department:
- Justice Department
- Entry Type:
- Notice
- Document Number:
- 95-13995
- Pages:
- 30318-30318 (1 pages)
- PDF File:
-
95-13995.pdf